{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:06:07Z","timestamp":1781258767998,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cukurova University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Orthop Trauma Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a considerable risk of recurrence, but reliable predictive markers are limited. High-temperature requirement A serine peptidase 1 (HtrA1) has been implicated in the progression of several cancers and may also play a role in GCTB recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective study included 34 patients with GCTB treated with curettage between 2002 and 2016. HtrA1 expression was evaluated separately in giant cells (GC) and mononuclear cells (MNC) using immunohistochemistry. Based on high or low expression in each cell type, patients were categorized into four expression patterns: High GC \/ High MNC, High GC \/ Low MNC, Low GC \/ High MNC, and Low GC \/ Low MNC. Clinical data, including recurrence status and time to recurrence, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The High GC \/ Low MNC group showed the highest recurrence rate at 71.4%, compared with 28.6% in the High GC \/ High MNC group and 31.6% in the Low GC \/ Low MNC group. No recurrence was observed in the Low GC \/ High MNC group, which included only one patient. The High GC \/ Low MNC group showed a non-significant trend toward higher recurrence compared with all other groups combined, with a similar trend toward shorter recurrence-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HtrA1 expression patterns in GCTB may provide preliminary insight into recurrence risk. Although no statistically significant association was demonstrated, the observed trends suggest potential prognostic relevance and warrant validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00402-026-06374-5","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:47:09Z","timestamp":1781257629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence"],"prefix":"10.1007","volume":"146","author":[{"given":"Akif","family":"Mirioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan Ali","family":"Dalkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Yigit","family":"Gokmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"Bagir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kivilcim Eren","family":"Ates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Deveci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclfiliz","family":"G\u00f6nl\u00fc\u015fen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilmi Serdar","family":"Ozbarlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"6374_CR1","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.2106\/JBJS.22.00404","volume":"104","author":"C Moore","year":"2022","unstructured":"Moore C, Fernandes RJ, Manrique J, Polissar NL, Miljacic L, Hippe DS, Vaux J, Thompson MJ (2022) Cytotoxic Effects of Common Irrigation Solutions on Chondrosarcoma and Giant Cell Tumors of Bone. J Bone Joint Surg Am 104:2153\u20132159. https:\/\/doi.org\/10.2106\/JBJS.22.00404","journal-title":"J Bone Joint Surg Am"},{"key":"6374_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11912-021-01047-5","volume":"23","author":"A Basu Mallick","year":"2021","unstructured":"Basu Mallick A, Chawla SP (2021) Giant Cell Tumor of Bone: An Update. Curr Oncol Rep 23:51. https:\/\/doi.org\/10.1007\/s11912-021-01047-5","journal-title":"Curr Oncol Rep"},{"key":"6374_CR3","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/curroncol31040157","volume":"31","author":"S Tsukamoto","year":"2024","unstructured":"Tsukamoto S, Mavrogenis AF, Masunaga T, Honoki K, Fujii H, Kido A, Tanaka Y, Errani C (2024) Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update. Curr Oncol 31:2112\u20132132. https:\/\/doi.org\/10.3390\/curroncol31040157","journal-title":"Curr Oncol"},{"key":"6374_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11999-010-1501-7","volume":"469","author":"FM Klenke","year":"2011","unstructured":"Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011) Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 469:591\u2013599. https:\/\/doi.org\/10.1007\/s11999-010-1501-7","journal-title":"Clin Orthop Relat Res"},{"key":"6374_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2106\/JBJS.17.00057","volume":"100","author":"C Errani","year":"2018","unstructured":"Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM (2018) Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage. J Bone Joint Surg Am 100:496\u2013504. https:\/\/doi.org\/10.2106\/JBJS.17.00057","journal-title":"J Bone Joint Surg Am"},{"key":"6374_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14670\/HH-18-486","volume":"38","author":"B Rekhi","year":"2023","unstructured":"Rekhi B, Dave V (2023) Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses. Histol Histopathol 38:139\u2013153. https:\/\/doi.org\/10.14670\/HH-18-486","journal-title":"Histol Histopathol"},{"key":"6374_CR7","doi-asserted-by":"publisher","unstructured":"Borkowska AM, Szumera-Cie\u0107kiewicz A, Szostakowski B, Pie\u0144kowski A, Rutkowski PL (2022) Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14092290","DOI":"10.3390\/cancers14092290"},{"key":"6374_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jos.2020.11.005","volume":"27","author":"K Hayashida","year":"2022","unstructured":"Hayashida K, Kawabata Y, Kato I, Kamiishi T, Matsuo K, Takeyama M, Inaba Y (2022) Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence. J Orthop Sci 27:215\u2013221. https:\/\/doi.org\/10.1016\/j.jos.2020.11.005","journal-title":"J Orthop Sci"},{"key":"6374_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4103\/ijpm.ijpm_886_23","volume":"67","author":"B Rekhi","year":"2024","unstructured":"Rekhi B, Dave V, Butle A, Dharavath B, Khetale S, Redhu AK, Singh R, Dutt A (2024) Immunohistochemical expression of H3.3 G34W in 100 giant cell tumors of bone and its diagnostic mimics, including its value in resolving uncommon diagnostic scenarios: A single institutional study at a tertiary cancer referral center, India. Indian J Pathol Microbiol 67:542\u2013552. https:\/\/doi.org\/10.4103\/ijpm.ijpm_886_23","journal-title":"Indian J Pathol Microbiol"},{"key":"6374_CR10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.31557\/APJCP.2023.24.5.1737","volume":"24","author":"UA Miskad","year":"2023","unstructured":"Miskad UA, Syamsul F, Dahlan H, Sungowati NK, Achmad D, Johan MP (2023) Significance of Histone H3.3 (G34W)-Mutant Protein in Pathological Diagnosis of Giant Cell Tumor of Bone. Asian Pac J Cancer Prev 24:1737\u20131741. https:\/\/doi.org\/10.31557\/APJCP.2023.24.5.1737","journal-title":"Asian Pac J Cancer Prev"},{"key":"6374_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40291-024-00712-2","volume":"28","author":"MA Rosochowicz","year":"2024","unstructured":"Rosochowicz MA, Kulcenty K, Suchorska WM (2024) Exploring the Role of HtrA Family Genes in Cancer: A Systematic Review. Mol Diagn Ther 28:347\u2013377. https:\/\/doi.org\/10.1007\/s40291-024-00712-2","journal-title":"Mol Diagn Ther"},{"key":"6374_CR12","doi-asserted-by":"publisher","first-page":"102329","DOI":"10.1016\/j.tice.2024.102329","volume":"87","author":"C Licini","year":"2024","unstructured":"Licini C, Fantone S, Lamanna D, Tossetta G, Marzioni D, Belmonte MM (2024) Possible involvement of HtrA1 serine protease in the onset of osteoporotic bone extracellular matrix changes. Tissue Cell 87:102329. https:\/\/doi.org\/10.1016\/j.tice.2024.102329","journal-title":"Tissue Cell"},{"key":"6374_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/modpathol.2016.212","volume":"30","author":"T Kervarrec","year":"2017","unstructured":"Kervarrec T, Collin C, Larousserie F, Bouvier C, Aubert S, Gomez-Brouchet A, Marie B, Miquelestorena-Standley E, Le Nail LR, Avril P, Christophe J, Pag\u00e8s G, de Pinieux (2017) H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach. Mod Pathol 30:393\u2013406. https:\/\/doi.org\/10.1038\/modpathol.2016.212","journal-title":"Mod Pathol"},{"key":"6374_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/ng.2814","volume":"45","author":"S Behjati","year":"2013","unstructured":"Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45:1479\u20131482. https:\/\/doi.org\/10.1038\/ng.2814","journal-title":"Nat Genet"},{"key":"6374_CR15","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00264-016-3292-2","volume":"40","author":"N Lujic","year":"2016","unstructured":"Lujic N, Sopta J, Kovacevic R, Stevanovic V, Davidovic R (2016) Recurrence of giant cell tumour of bone: role of p53, cyclin D1, \u03b2-catenin and Ki67. Int Orthop 40:2393\u20132399. https:\/\/doi.org\/10.1007\/s00264-016-3292-2","journal-title":"Int Orthop"},{"key":"6374_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2217\/14622416.9.8.1069","volume":"9","author":"A Baldi","year":"2008","unstructured":"Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, Citro G, Ceribelli A, Mirri A, Chien J, Shridhar V, Ehrmann M, Santini M, Facciolo F (2008) The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 9:1069\u20131077. https:\/\/doi.org\/10.2217\/14622416.9.8.1069","journal-title":"Pharmacogenomics"},{"key":"6374_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12282-020-01159-z","volume":"28","author":"GFA Carrara","year":"2021","unstructured":"Carrara GFA, Evangelista AF, Scapulatempo-Neto C, Abrah\u00e3o-Machado LF, Morini MA, Kerr LM, Folgueira MAAK (2021) da Costa Vieira, Analysis of RPL37A, MTSS1, and HtrA1 expression as potential markers for pathologic complete response and survival. Breast Cancer 28:307\u2013320. https:\/\/doi.org\/10.1007\/s12282-020-01159-z","journal-title":"Breast Cancer"},{"key":"6374_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/jcb.10578","volume":"89","author":"AIC Si","year":"2003","unstructured":"Si AIC, Huang L, Xu J, Kumta S-M, Wood D, Zheng MH (2003) Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. J Cell Biochem 89:1154\u20131163. https:\/\/doi.org\/10.1002\/jcb.10578","journal-title":"J Cell Biochem"},{"key":"6374_CR19","doi-asserted-by":"publisher","first-page":"e17595","DOI":"10.1016\/j.heliyon.2023.e17595","volume":"9","author":"L Chen","year":"2023","unstructured":"Chen L, Zhong Y, Sun S, Yang Z, Hong H, Zou D, Song C, Li W, Leng H (2023) HtrA1 from OVX rat osteoclasts causes detrimental effects on endplate chondrocytes through NF-\u03baB. Heliyon 9:e17595. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17595","journal-title":"Heliyon"},{"key":"6374_CR20","doi-asserted-by":"publisher","first-page":"21335","DOI":"10.1074\/jbc.M112.341032","volume":"287","author":"AN Tiaden","year":"2012","unstructured":"Tiaden AN, Klawitter M, Lux V, Mirsaidi A, Bahrenberg G, Glanz S, Quero L, Liebscher T, Wuertz K, Ehrmann M, Richards PJ (2012) Detrimental role for human high temperature requirement serine protease A1 (HtrA1) in the pathogenesis of intervertebral disc (IVD) degeneration. J Biol Chem 287:21335\u201321345. https:\/\/doi.org\/10.1074\/jbc.M112.341032","journal-title":"J Biol Chem"},{"key":"6374_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/ten.TEC.2013.0724","volume":"21","author":"D Ollitrault","year":"2015","unstructured":"Ollitrault D, Legendre F, Drougard C, Briand M, Benateau H, Goux D, Chajra H, Poulain L, Hartmann D, Vivien D, Shridhar V, Baldi A, Mallein-Gerin F, Boumediene K, Demoor M, Galera P (2015) BMP-2, hypoxia, and COL1A1\/HtrA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes. Tissue Eng Part C Methods 21:133\u2013147. https:\/\/doi.org\/10.1089\/ten.TEC.2013.0724","journal-title":"Tissue Eng Part C Methods"},{"key":"6374_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ygyno.2006.03.006","volume":"103","author":"MA Bowden","year":"2006","unstructured":"Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA, Nie G (2006) Serine proteases HtrA1 and HtrA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol 103:253\u2013260. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.006","journal-title":"Gynecol Oncol"},{"key":"6374_CR23","doi-asserted-by":"publisher","first-page":"119553","DOI":"10.1016\/j.bbamcr.2023.119553","volume":"1870","author":"Z Tong","year":"2023","unstructured":"Tong Z, Shen Y, Yuan Q, Yu H (2023) HtrA3 transcriptionally inhibited by FOXP1 suppresses tumorigenesis of osteosarcoma via the PTEN\/PI3K\/AKT pathway. Biochim Biophys Acta Mol Cell Res 1870:119553. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119553","journal-title":"Biochim Biophys Acta Mol Cell Res"}],"container-title":["Archives of Orthopaedic and Trauma Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06374-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00402-026-06374-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06374-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:47:11Z","timestamp":1781257631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00402-026-06374-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6374"],"URL":"https:\/\/doi.org\/10.1007\/s00402-026-06374-5","relation":{},"ISSN":["1434-3916"],"issn-type":[{"value":"1434-3916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were performed following written informed patient consent and by the ethical standards of the institutional and national research committee and the 1964 Declaration of Helsinki. Ethical approval for this study was approved by our institutional review board (\u00c7ukurova University, Adana, Turkey). All the data were analyzed anonymously, and personal identifiers were completely deleted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"214"}}